NangioTx, Inc.Wins Mid-Atlantic Bio Angels’ “Best of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NangioTx, Inc.Wins Mid-Atlantic Bio Angels’ “Best of the Best” Year-End 1st Pitch Life Science Competition

NEW YORK , Dec. 13, 2016 (GLOBE NEWSWIRE) -- Mid-Atlantic Bio Angels (MABA) announces today that NangioTx, Inc.( http://www.nangiotx.com ) was voted as “Best of the Best” among past winners of MABA's 1st Pitch Life Science events for 2016.  The competition took place on December 6, 2016, at Medidata Solutions at 350 Hudson Street in New York City.  NangioTx is a Houston-based drug development company developing a novel drug that promotes the growth of new blood vessels in the muscles of patients with peripheral artery disease, which causes muscle atrophy and cell death.

"Nine companies that have previously won ‘Best in Show’ titles in 2016 1st Pitch competitions competed for the coveted ‘Best of the Best’ title at MABA's end of year competition.  All the previous winners had significantly improved their pitches, and the competition was fierce,” said Yaniv Sneor, MABA co-founder and president of Blue Cactus Consulting. “Vivek Kumar, NangioTx's CEO, delivered a compelling and engaging pitch that won the majority of audience votes, and the well-earned title of 2016 ‘Best of the Best.’ I see a bright future for him and his company.” “We left the 1 st Pitch competition in February with a number of ideas of how to improve the approach to our business plan, while continuing to pursue our science. We are grateful to have been able to apply that knowledge in order to be chosen as ‘Best of the Best,’ said Vivek Kumar, Ph.D., co-founder and CEO of NangioTx. “Peripheral artery disease sufferers remain an extremely underserved population – more than 8 million Americans – and we are dedicated to developing a potential treatment to preserve their muscle tissue for as long as possible.”

NangioTx’s flagship product, V-10,is a thixotropic self-assembling peptide drug that promotes angiogenesis for muscle preservation. V-10 presents a mimic of VEGF in much higher epitope density stimulating localized blood vessel growth in an injectable hydrogel. V-10 has shown therapeutic benefit in the preclinical efficacy model of peripheral artery disease (PAD). Studies of the drug demonstrate that it improves perfusion and gait in the mice with hind limb ischemia. The company is currently developing it for evaluation in a Phase I clinical trial for intermittent claudication in PAD.

“After more than two hours of pitches and despite being second to the last of the nine presenters, the audience of nearly 150 who remained through the evening expressed great enthusiasm for NangioTx’s pitch and its revascularization technology,” added Stephen M. Goodman, co-founder of MABA and a partner at New York law firm Pryor Cashman, LP. “1 st Pitch advertises that its presenting companies are not quite ready for investment.  NangioTx’s pitch, like the other pitches at this event, showed that Vivek Kumar took the assessments offered at the company’s earlier presentation this year and used them to advance the case that his company may, in fact, be ready.”

As winner of “Best of the Best,” NangioTx will receive select services free of charge from sponsors of the event, including, intellectual property counsel from Wilson Sonsini Goodrich & Rosati; FDA counsel from BakerHostetler; general corporate, corporate governance and finance counsel from McCarter & English, LLP; technology transfer and licensing counsel from Pryor Cashman, LP; business commercialization strategy and execution from Blue Cactus Consulting; a free press release developed by JQA Partners, Inc.; and advisory on becoming desirable to investors from Capgenic Advisors.

About NangioTx NangioTx is a Houston-based company developing a platform regenerative technology to engineer tissue by returning blood flow to dying organs.  Reduced blood flow (ischemia) to the legs in peripheral artery disease results in tissue damage and ultimately limb amputation or death.  NangioTx’s flagship technology, V-10, is an injectable material that helps create new blood vessels.  V-10 promotes growth and maturity of new vessels through proprietary, patent pending technology.

About Mid Atlantic Bio Angels Mid Atlantic Bio Angels (http://bioangels.net) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA's goal is to create an environment where the depth of investors' knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.

CONTACT: Jules Abraham JQA Partners, Inc. jabraham@jqapartners.com 917-885-7378

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 211

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
NeuroPace Faces Investigation After Revenue Forecast Cut

Updated Category News Views 35

NeuroPace Revenue Drama: A Blow to Investor Confidence How the mighty have stumbled—or so it feels to the folks who put their bucks into NeuroPace, Inc. (NASDAQ: NPCE). It's tough to swallow: they cut their 2026 revenue forecast from a hopeful $99.5-$101.5 million to a sobering $91-$92 million. Just one quarter apart those projections are, like a cruel twist of fate...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 155

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
AppLovin Faces Legal Heat: Investors on Edge Today

Updated Category News Views 104

AppLovin's Day of Reckoning: Investors Take Note Ever find yourself caught in a whirlwind of corporate promises that slide into disappointment? Well, buckle up, because that's exactly where AppLovin finds itself today. They've stirred up a storm with investors over some questionable hyperbole about their artificial intelligence tools and ad services. Missteps and Market...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 189

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 123

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 68

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Operation Healing Forces Partners with Wounded Warrior

Updated Category News Views 56

Joining Forces for Special Operations Families When it comes to the heavy lifting of supporting Special Operations Forces (SOF) families, two powerhouses—Operation Healing Forces (OHF) and Wounded Warrior Project (WWP)—are doubling down. They’re not just tossing around good intentions. Oh no, they’re pulling out the stops with a solid partnership focused on...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 126

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 142

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Nauticus Robotics Reports Exciting Q3 2025 Financial Results

Updated Category News Views 251

Nauticus Robotics Shows Strong Performance in Q3 2025 Nauticus Robotics, Inc. (NASDAQ: KITT), an industry leader in subsea robotics, has recently made headlines with their impressive financial performance during the third quarter of 2025. This period marked a remarkable increase in customer interest, innovative capabilities, and upcoming product launches that promise to...

Continue Reading
Nano Labs' Strategic Move to Nasdaq Global Market: Key Benefits

Updated Category News Views 152

Nano Labs Elevates to Nasdaq Global Market Nano Labs Ltd (Nasdaq: NA), a frontrunner in Web 3.0 infrastructure and product solutions, has officially announced its uplisting to the Nasdaq Global Market. This significant move is designed to provide enhanced opportunities for growth and stability, marking an exciting chapter for the company and its shareholders. Impact of...

Continue Reading
The EVERY Company Strengthens Its Patent Portfolio in Europe

Updated Category News Views 169

The EVERY Company Enhances Its Intellectual Property The EVERY Company, a prominent innovator in protein ingredients, has recently secured a significant patent for its recombinant ovalbumin in the European Union. This development consolidates its position as a leader in crafting functional protein ingredients, paving the way for its growth and expansion within the global...

Continue Reading
Discover the Compounding Success of Analog Devices Over a Decade

Updated Category News Views 204

How $100 Invested in Analog Devices Transformed Over 10 Years Analog Devices (NASDAQ: ADI) has had a remarkable journey over the past decade, outperforming the market with an annualized growth of 2.67%, resulting in an impressive average annual return of 14.15%. As of the latest figures, Analog Devices boasts a market capitalization of approximately $118.16 billion. The...

Continue Reading
Mustang Bio Secures $8 Million in Public Offering Success

Updated Category News Views 118

Mustang Bio Completes $8 Million Public Offering Mustang Bio, Inc. (Nasdaq: MBIO), a prominent company in the biopharmaceutical sector, renowned for its innovative cell therapies, recently announced the successful closure of a public offering that raised approximately $8 million. This financial milestone signifies a major step forward for the company as it aims to drive...

Continue Reading